Lenalidomide-based combined therapy induced alterations in serum proteins of multiple myeloma patient: A follow-up case report and overview of the literature

Experimental Oncology

Volumn 34, Issue 4, 2012, Pages 373-376

  Senthilkumar, C S ^a   Ganesh, N ^a  

^a Jawaharlal Nehru Cancer Hospital & Research Centre Bhopal   (India)

Author keywords

Disease response monitoring; Lenalidomide based combined therapy; Multiple myeloma; Serum protein alterations; Three visits follow up

Indexed keywords

ALBUMIN; ALPHA 2 GLOBULIN; AMIKACIN; DEXAMETHASONE; ENOXAPARIN; HEMOGLOBIN; IBANDRONIC ACID; IMMUNOGLOBULIN; LENALIDOMIDE; METOCLOPRAMIDE; MORPHINE; NITROFURANTOIN; UREA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; FEMALE; FOOT EDEMA; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LEUKOCYTE COUNT; LOW BACK PAIN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOPOROSIS; PAIN; PROTEIN ANALYSIS; PROTEIN ELECTROPHORESIS; TREATMENT DURATION; TREATMENT RESPONSE; UREA BLOOD LEVEL; WEAKNESS; WHOLE BODY SCINTISCANNING; ZONE ELECTROPHORESIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84872414340     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-72.
2. Lynch HT, Sanger WG, Pirruccello S, et al. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2001; 93: 1479-83. (Pubitemid 32982677)
3. IMWG (International Myeloma Working Group). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-57.
4. Fentress DS, Orrico LA, Kruspe M, Briscoe K, et al. Multiple myeloma. Hospital Physician 2006; 42: 15-25.
5. O'Connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician 2005; 71: 105-12. (Pubitemid 40096059)
6. Kyle RA. Update on the treatment of multiple myeloma. Oncologist 2001; 6: 119- 24.
7. Richardson PG, Mitsiades C, Schlossman R, Munshi N, et al. New drugs for myeloma. Oncologist 2007; 12: 664-89. (Pubitemid 47036203)
8. Palumbo A, Miguel Js, Sonneveld P, et al. Lenalidomide: A new therapy for multiple myeloma. Cancer Treat Reviews 2008; 34: 283-91.
9. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011; 17: 1264-77.
10. Vallet S, Palumbo A, Raje N, Boccadoro, et al. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 2008; 49: 1238-45. (Pubitemid 352015786)
11. Crane E, List A. Lenalidomide: an immunomodulatory drug. Future Oncol 2005; 1: 1-5.
12. List AF, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control 2006; 13: 4-11. (Pubitemid 46148104)
13. Volk C, Klein U. Management of multiple myeloma and myelodysplastic syndrome: focus on lenalidomide. Clinical Medicine: Therapeutics 2009; 1: 95-102.
14. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-73.
15. Senthilkumar CS, Ujjwala K, Sameena A, Ganesh N. Consistency pattern of liver functioning, serum proteins and genomic DNA in hematological malignancies: a comparative clinical study in 4 cases of chronic and acute leukemia's. Int J Cell Mol Biol 2010; 1: 19-25.
16. Senthilkumar CS, Malla TM, Ujjwala K, Sameena A, et al. Amido black 10 B is preferable to Ponceau S stain for staining Serum proteins in electrophoretic studies for clinical diagnosis. J Ult Sci Phy Sci 2009; 21: 105-8.
17. Piazza FA, Gurrieri C, Trentin L, Semenzato G. Towards a new age in the treatment of multiple myeloma. Ann Hematol 2007; 86: 159-72. (Pubitemid 46195988)
18. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
19. Hideshima T, Richardson PG, Anderson KC. Current therapeutic uses of lenalidomide in Multiple myeloma. Expert Opi Invest Drugs 2006; 15: 171-9. (Pubitemid 43250758)
20. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase II study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-64.
21. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. The New Eng J Med 2007; 357: 2133-42. (Pubitemid 350146108)
22. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete - and overall response rates in treatment-naive symptomatic multiple myeloma. Blood 2008; 111: 1101-9. (Pubitemid 351213388)
23. Fahey JL, Boggs DR. Serum protein changes in malignant diseases. I. The acute leukemia's. Blood 1960; 16: 1479-90.